Page 85 - MemoriaES-Eng

www.ciberes.org

• A Mg, l i, d J, M J, M i, e-o J. Dried plasma spots in
Most relevant ABYeAtorreiAZAldonAdoiAldeAugenlSen
the diagnosis of tuberculosis: IP-10 release assay on filter paper.Eur Respir J. 2013
scientific Aug;42(2):495-503.

articles
• VilAPlAnA c, MArZo e, tAPiA g, diAZ J, gArcíA V, cArdonA PJ. Ibuprofen therapy resulted in
significantly decreased tissue bacillary loads and increased survival in a new murine

experimental model of active tuberculosis.J Infect Dis. 2013 Jul 15;208(2):199-202.

• AuSinA ruiZ V, FernándeZ-riVAS g, VilAPlAnA MeSSeguer c. Selected culture and drug-
susceptibility testing methods for drug-resistant Mycobacterium tuberculosis scree-

ning in resource-constrained settings.Expert Rev Mol Diagn. 2013 Apr;13(3):247-9.

• VillellAS c, AriStiMuño l, VitoriA MA, PrAt c, BlAnco S, gArcíA de ViedMA d. Analysis of
mutations in streptomycin-resistant strains reveals a simple and reliable genetic

marker for identification of the Mycobacterium tuberculosis Beijing genotype.J Clin
Microbiol. 2013 Jul;51(7):2124-30.

• A A, A Ji, g-A J, M d, u S, P e. Construction,
rBueSguiloonZAloSenSioArinoVArAngAuenteS
characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tu-

berculosis-based vaccine to enter clinical trials.Vaccine. 2013 Oct 1;31(42):4867-73.

Following the WHO priorities stated in the “Global Plan to Stop TB 2006-2015”,
Highlights
over the last few years researchers belonging to group 17 within CIBERES have ge-

nerated considerable scientific knowledge, with an emphasis on joint publications
involving groups form different Programs and collaborations with other national

and international groups in the context of the pathogenesis, prevention, diagno-

sis and treatment of tuberculosis. The researchers of this group have continued
investigating new prophylactic and therapeutic vaccines against tuberculosis, and

have also developed new experimental animal models that better reproduce in-
fection and disease in humans. Studies have also been carried out that provide

new insights into the resistance of M. tuberculosis and multi-drug resistant TB.

New procedures have been developed and evaluated for the molecular typing of
M. tuberculosis for epidemiological purposes. New immunological techniques to

diagnose latent tuberculosis infection have also been evaluated. As a result of this

work, the researchers have actively participated in the development of clinical
guidelines for the use of new diagnostic tests (interferon-gamma release assays-

IGRAs) for latent tuberculosis infection.

Group 17 members have also developed several research projects related to other
respiratory pathogens: S. aureus, M. pneumoniae, S. pneumoniae, H. influenzae

and respiratory viruses. One line of research in which the group has been active in

recent years is the assessment of the importance of the inflammatory response in
respiratory tract infections. The main objective is to identify and describe patho-

gen and host factors that modulate clinical outcome.
13
Researchers belonging to group 17 are currently involved in five projects funded 20
T
by the EU in the FP7 framework, and in several research projects funded by na- OR
tional agencies (FIS, Ministry of Economy and Competitiveness and others), the P
RE
industry and the Administration. We have also developed scientific collaboration L
with other CIBER (CIBER-BBN, CIBEResp, and others).
A
NU
The research activities of the group have recently generated six new patents and N
A
created a spin-off with the aim of commercializing a new probiotic that may allow S /
E
treatment shortening in latent tuberculosis infections.
ER
B
CI

85